Primary Breast Lymphomas: A Retrospective Analysis of Twelve Cases

Barışta, İbrahim; Tekuzman, G.; Kars, Ayse; Ruacan, Şevket; Özışık, Yavuz; Güler, Nilüfer; Güllü, İbrahi̇m; Atahan, I. Lale; Firat, D.

doi:10.1080/028418600430671

Cited by 44 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median age of the women in our study was 47.6 years, slightly lower than the median age of 55-60 years reported in other studies [7,[12][13][14][15][16][17]. The majority of our patients presented with localized disease (79%), which is in contrast to a similar study of 14 Chinese female patients with breast lymphoma from Hong Kong [18].…”

Section: Discussioncontrasting

confidence: 55%

Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy

Choo

Lim²,

Wong³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Purpose: This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution. Patients and Methods: We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003. Results: All patients were female, with a median age of 47.6 years. Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt’s, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each. 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease. Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt’s lymphoma received a CHOP-based regimen. The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%. Among those with localized disease, the estimated 3-year survival was 90%. The actuarial 3-year overall survival (OS) estimate for the entire cohort of 14 patients was 76.9%. Conclusion: Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.

show abstract

Section: Discussioncontrasting

confidence: 55%

Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy

Choo

Lim²,

Wong³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Our results confirm that combined therapy appears to be superior in EFS and overall survival when compared to radiotherapy and chemotherapy alone. Relapse in the CNS has frequently been reported [4, 6, 13]. Our series shows that relapse in these anatomical sites was 9.4% and this complication was lethal in all cases.…”

Section: Discussionmentioning

confidence: 57%

“…Different therapeutic approaches have been considered: surgery, radiotherapy, chemotherapy or well-combined two or three therapeutic modalities. No definite conclusions can be drawn because most reports include different histology, different stage (including advanced or disseminated disease) and different treatments and schedules [1,3,4,5,6, 9]. We began a controlled clinical trial to define the efficacy and toxicity of the most common type of therapeutic options for this type of malignant lymphoma.…”

Section: Introductionmentioning

confidence: 99%

“…Varying frequencies have been reported, but in most series it is less than 0.7% of all breast malignancies and less than 1% of all non-Hodgkin’s lymphomas. Clinical presentation and radiological findings do not differ from breast cancer and the diagnosis is based on pathological material [1,2,3,4,5,6,7,8]. Different therapeutic approaches have been considered: surgery, radiotherapy, chemotherapy or well-combined two or three therapeutic modalities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary Breast Lymphoma: Results of a Controlled Clinical Trial

Avilés¹,

et al. 2005

View full text Add to dashboard Cite

Objectives: To assess the efficacy and toxicity of the most employed therapeutic approaches in the treatment of primary breast lymphoma (PBL). Methods: Ninety-six patients with PBL in the early stage (I or II) were enrolled to receive radiotherapy (45 Gy); chemotherapy (six cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), every 21 days), or combined therapy. Results: Complete response was achieved in 20 of 30 patients treated with radiotherapy, 19 of 32 who were treated with chemotherapy and 30 of 34 in the combined arm (p < 0.01). Actuarial curves at 10 years showed that event-free survival was 50, 57 and 83%, respectively (p < 0.01). Actuarial curves for overall survival were 50, 50 and 76% (p < 0.01), respectively. The most common site of relapse was the central nervous system. Acute toxicity was mild. Until now, no second neoplasm or acute leukemia has been observed. Conclusions: In our study combined therapy is the best treatment in this special setting of patients; with improvement in event-free survival and overall survival without acute or severe late side effects. Prophylaxis to the central nervous system will be considered in the initial treatment to improve outcome.

show abstract

“…In young patients, the disease presents bilaterally and may clinically mimic inflammatory breast cancer. Most are highly aggressive, as in Burkitt type 2,7 . The clinical presentation may also be associated with systemic B symptoms: fever, weight loss and night sweats.…”

Section: Discussionmentioning

confidence: 99%

Non-Hodgkin lymphoma in breast: case report

Pedrini¹,

Schorr²,

Munaretto³

et al. 2017

Rev. Bras. Mastol. (Impr.)

View full text Add to dashboard Cite

The primary breast lymphoma is a rare tumor, accounting for up to 0.5% of breast cancers. Most primary breast lymphoma is presented as non-Hodgkin lymphoma, the B-cells lymphoma is the most common, and Burkitt lymphoma is the most aggressive. We report the case of a 24-year-old female patient, with global, progressive and rapid increase of the right breast during 30 days with reaction to insect bite and progressive weight loss, fatigue, fever and nocturne sweating. An echo-guided core biopsy was held with injury and showed an atypical lymphoid proliferation, suggestive of high-grade non-Hodgkin lymphoma. Immunohistochemistry confirmed non-Hodgkin lymphoma, B immunophenotype, Burkitt type. Also, the diagnosis of HIV infection was performed during hospitalization. Patient started with multidrug chemotherapy scheme and antiretroviral therapy. Burkitt lymphoma is an exceptionally aggressive subtype and can affect the central nervous system and gastrointestinal tract, and treatment consists of chemotherapy with multiple agents as soon as possible. Radiotherapy has no function in the Burkitt type cases, even in case of only local disease. RESUMO

show abstract

Primary Breast Lymphomas: A Retrospective Analysis of Twelve Cases

Cited by 44 publications

References 25 publications

Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy

Breast Lymphoma: Favorable Prognosis after Treatment with Standard Combination Chemotherapy

Primary Breast Lymphoma: Results of a Controlled Clinical Trial

Non-Hodgkin lymphoma in breast: case report

Contact Info

Product

Resources

About